Literature DB >> 11410611

Expression of cyclo-oxygenase-2 in naturally occurring squamous cell carcinomas in dogs.

E M Pestili de Almeida1, C Piché, J Sirois, M Doré.   

Abstract

Squamous cell carcinoma is one of the most common cancers in humans and is also a frequently diagnosed neoplasm in dogs. Induction of cyclo-oxygenase-2 (COX-2), a key rate-limiting enzyme in prostaglandin biosynthesis, has been implicated in the oncogenesis of various cancers in humans, including squamous cell carcinomas. However, expression of COX-2 has not been reported in spontaneous squamous cell carcinomas of non-human species. Canine squamous cell carcinomas share several similarities with the human disease. Therefore, the objective of this study was to determine whether COX isoenzymes were expressed in naturally occurring cases of squamous cell carcinomas in dogs. Canine normal skin (n=4) and squamous cell carcinomas (n=40) were studied by immunohistochemistry and immunoblotting analysis using polyclonal antibodies selective for COX-1 or COX-2. COX-2 was strongly expressed by neoplastic keratinocytes in all cases of squamous cell carcinomas, whereas no COX-2 was detected in normal skin and in the non-neoplastic skin and oral mucosa included in the tumor tissue samples (p<0.01). Immunoblotting analysis confirmed the restricted expression of COX-2 (72,000--74,000 molecular weight doublet) in squamous cell carcinomas only. In contrast, faint COX-1 staining was found in normal skin and in squamous cell carcinomas. This study demonstrates for the first time that COX-2 is induced in canine squamous cell carcinomas, and provides a new model to investigate the role and regulation of COX-2 gene expression in naturally occurring squamous cell carcinomas. (J Histochem Cytochem 49:867-875, 2001)

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11410611     DOI: 10.1177/002215540104900707

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  11 in total

1.  Doxorubicin and deracoxib adjuvant therapy for canine splenic hemangiosarcoma: a pilot study.

Authors:  S Anthony Kahn; Christine M Mullin; Louis-Philippe de Lorimier; Kristine E Burgess; Rebecca E Risbon; Rogers M Fred; Kenneth Drobatz; Craig A Clifford
Journal:  Can Vet J       Date:  2013-03       Impact factor: 1.008

2.  Molecular imaging of cyclooxygenase-2 in canine transitional cell carcinomas in vitro and in vivo.

Authors:  Maria Cekanova; Md Jashim Uddin; Joseph W Bartges; Amanda Callens; Alfred M Legendre; Kusum Rathore; Laura Wright; Amanda Carter; Lawrence J Marnett
Journal:  Cancer Prev Res (Phila)       Date:  2013-03-26

3.  Lipids and FA analysis of canine prostate tissue.

Authors:  Nadia M Attar-Bashi; Karyn Orzeszko; Ronald F Slocombe; Andrew J Sinclair
Journal:  Lipids       Date:  2003-06       Impact factor: 1.880

4.  Prostaglandin synthesis, metabolism, and signaling potential in the rhesus macaque corpus luteum throughout the luteal phase of the menstrual cycle.

Authors:  Randy L Bogan; Melinda J Murphy; Richard L Stouffer; Jon D Hennebold
Journal:  Endocrinology       Date:  2008-07-17       Impact factor: 4.736

5.  Single-dose safety and pharmacokinetic evaluation of fluorocoxib A: pilot study of novel cyclooxygenase-2-targeted optical imaging agent in a canine model.

Authors:  Maria Cekanova; Md Jashim Uddin; Alfred M Legendre; Gina Galyon; Joseph W Bartges; Amanda Callens; Tomas Martin-Jimenez; Lawrence J Marnett
Journal:  J Biomed Opt       Date:  2012-11       Impact factor: 3.170

Review 6.  Animal models and therapeutic molecular targets of cancer: utility and limitations.

Authors:  Maria Cekanova; Kusum Rathore
Journal:  Drug Des Devel Ther       Date:  2014-10-14       Impact factor: 4.162

Review 7.  Non-murine models to investigate tumor-immune interactions in head and neck cancer.

Authors:  Carlos Rossa; Nisha J D'Silva
Journal:  Oncogene       Date:  2019-03-14       Impact factor: 9.867

8.  Animal model of naturally occurring bladder cancer: characterization of four new canine transitional cell carcinoma cell lines.

Authors:  Kusum Rathore; Maria Cekanova
Journal:  BMC Cancer       Date:  2014-06-25       Impact factor: 4.430

9.  Pharmacokinetic characterization of fluorocoxib D, a cyclooxygenase-2-targeted optical imaging agent for detection of cancer.

Authors:  Maria Cekanova; Sony Pandey; Shelly Olin; Phillip Ryan; Jennifer E Stokes; Silke Hecht; Tomas Martin-Jimenez; Md Jashim Uddin; Lawrence J Marnett
Journal:  J Biomed Opt       Date:  2020-08       Impact factor: 3.170

10.  Detection of tyrosine kinase inhibitors-induced COX-2 expression in bladder cancer by fluorocoxib A.

Authors:  Jennifer Bourn; Sony Pandey; Jashim Uddin; Lawrence Marnett; Maria Cekanova
Journal:  Oncotarget       Date:  2019-08-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.